Bioxytran (BIXT) investor relations material

Key technology and scientific approach

• Focus on developing drugs based on polysaccharides targeting galectin receptors on viruses, aiming for broad-spectrum antiviral activity against viruses like COVID-19, influenza, RSV, and more.

• Utilizes galectin antagonists to block viral infection mechanisms, a novel approach distinct from immune-modulating antivirals.

• Drug design leverages AI, NMR, and structural biology to create molecules tailored to viral galectin profiles.

• Technology enables rapid adaptation to new viruses due to the conserved nature of galectin receptors.

• Approach is positioned as a potential paradigm shift in antiviral treatment, likened to antibiotics for viruses.

Clinical development and results

• Phase I and II clinical trials conducted in the US and India showed rapid viral clearance, with 88% of patients testing negative for virus by day three and 100% by day seven.

• No adverse effects reported; drug is based on FDA-approved polysaccharide chemistry.

• Ongoing confirmatory phase II trial is analyzing dose response, with results expected soon.

• If confirmed, results could represent a major advance in antiviral therapy, with potential for both treatment and prophylaxis.

• Plans for phase III trials targeting multiple viruses, with regulatory strategy including nutraceutical commercialization and eventual drug approval.

Commercial and strategic outlook

• Antiviral market opportunity estimated at $80 billion, with significant interest in large-scale manufacturing and supply chain capacity.

• Strategy includes early commercialization as a nutraceutical while pursuing full drug approval.

• Patent protection in place for both structure and use of the technology.

• Management team includes experts in chemistry, structural biology, and device development.

• Company is publicly traded, with a limited shareholder base and a current valuation between $5 and $7 million.